Diarrhea News and Research

Latest Diarrhea News and Research

Under-five mortality rate continues to decline

UNICEF today released new figures that show the rate of deaths of children under five years of age continued to decline in 2008.

11 Sep 2009

Students do not comply with basic preventative measures to combat H1N1

As public health experts warn of potential widespread outbreaks of H1N1 flu this school year, a new study from North Carolina State University shows that students do not comply with basic preventative measures as much as they think do. In other words, the kids aren't washing their hands.

11 Sep 2009

FDA approves Supplemental New Drug Application for DOXIL

Centocor Ortho Biotech Products, L.P. today announced that it received a Complete Response letter from the U.S. Food and Drug Administration (FDA) regarding its Supplemental New Drug Application (sNDA) for DOXIL (doxorubicin HCI liposome injection) in combination with docetaxel for the treatment of women with locally advanced and metastatic breast cancer.

10 Sep 2009

UNICEF data shows global child mortality now below 9m, progress not enough to achieve MDG in most regions

The annual number of deaths among children younger than five worldwide "has fallen below nine million" compared with 12.5 million in 1990, according to new data from UNICEF, the New York Times reports. "That's 10,000 less children dying per day," Ann Veneman, UNICEF's executive director, said.

10 Sep 2009

South East Asian health ministers adopt declaration to improve disaster preparedness, address childhood diarrhea

Health ministers from 11 member states in the WHO's South East Asian region on Tuesday at the 62nd session of the WHO Regional Committee for South East Asia adopted the Kathmandu Declaration on Protecting Health Facilities from Disasters, which commits them to make health facilities better prepared for health emergencies, Republica reports.

10 Sep 2009

Caldolor launched ahead of schedule in U.S. by Cumberland Pharmaceuticals

Cumberland Pharmaceuticals Inc. (Nasdaq: CPIX) announced today that it has successfully implemented the U.S. launch of Caldolor((R)), an intravenous formulation of ibuprofen, designed primarily for use in the hospital setting.

9 Sep 2009

Ceragenix awarded $2.87M NIH grant to develop a drug for treating Clostrdium difficile and Shigella

Ceragenix Pharmaceuticals, Inc. (“Ceragenix”) (OTCBB:CGXP), a medical device company focused on infectious disease and dermatology, today announced that the National Institutes of Health (“NIH”) has awarded a $2.87 million grant to fund the pre clinical development of a Ceragenin™based oral drug to treat two common and potentially deadly gastrointestinal infections: Clostrdium difficile and Shigella.

9 Sep 2009

Meda launches EDLUAR in the U.S.

Meda Pharmaceuticals Inc. (Meda) today announced the commercial availability of EDLUAR(TM) (zolpidem tartrate sublingual tablets) in the United States. EDLUAR is indicated for the short-term treatment of insomnia characterized by difficulties with falling asleep. EDLUAR is the first available under-the-tongue formulation of zolpidem tartrate, which is the most prescribed treatment for insomnia. Zolpidem tartrate is also the active ingredient in Ambien(R) oral tablets.

9 Sep 2009

Study to test efficacy of lapatinib in advanced hepatocellular carcinoma

Use of the molecularly targeted agent lapatinib to delay tumor growth and improve the survival of patients with inoperable hepatocellular carcinoma, or liver cancer, only benefited certain subgroups of patients. While results of this study were largely negative, patients that exhibited toxicity from the drug in the form of a skin rash appeared to have a greater tumor response and longer survival.

9 Sep 2009

DOR's Phase 1/2 clinical trial for prevention of radiation enteritis receives NIH grant

DOR BioPharma, Inc. (OTC Bulletin Board: DORB) (DOR or the Company), a late-stage biotechnology company, announced today that the National Institutes of Health (NIH) has awarded DOR a Small Business Innovation Research (SBIR) grant to support the conduct of a Phase 1/2 clinical trial evaluating DOR201, a time-release formulation of oral beclomethasone dipropionate (oral BDP), for the prevention of acute radiation enteritis.

8 Sep 2009

Third human clinical trial of LigoCyte's norovirus vaccine started

LigoCyte Pharmaceuticals, Inc. announced today that it has initiated its third human clinical trial of its norovirus vaccine. The Phase I/II study will assess safety and immunogenicity associated with LigoCyte's investigational, nasally-delivered, dry powder vaccine in healthy adults. The study will also assess potential protection against clinical symptoms of norovirus infection by including a live virus challenge of subjects that have received either the vaccine or placebo.

8 Sep 2009

Results of Phase 2 rheumatoid arthritis clinical trial announced

Array BioPharma Inc. (Nasdaq: ARRY) announced its preliminary analysis of results from a study examining ARRY-162, a small molecule MEK inhibitor, in a 12-week Phase 2 clinical trial with 201 patients.

4 Sep 2009

Recurrence of Clostridium difficile infection is a growing area of concern in hospitals

Arlington Medical Resources (AMR) and Decision Resources find that relapse or recurrence of infections is the most challenging aspect of treating Clostridium difficile infections in the hospital setting.

3 Sep 2009

Millennium's sNDA to be reviewed by the FDA

The Takeda Oncology Company today announced the U.S. Food and Drug Administration (FDA) has accepted for review the Company’s supplemental new drug application (sNDA) based on long- term overall survival (OS) data from the landmark VISTA1 trial examining the use of VELCADE based therapy in patients with previously untreated multiple myeloma (MM).

3 Sep 2009

Antibiotic used to treat trachoma reduces child mortality in Ethiopia, study finds

The antibiotic used to treat trachoma, "the world's leading preventable cause of blindness," may also protect children living in Ethiopia from death from of other diseases, according to a recent study, the Associated Press reports.

2 Sep 2009

FDA: Randomized clinical trial necessary to better interpret Clolar’s efficacy and safety in adult AML

Genzyme Corporation (Nasdaq: GENZ) announced today that the FDA’s Oncologic Drugs Advisory Committee voted 9 to 3 that a randomized, controlled trial is needed to support the currently proposed label expansion for Clolar® (clofarabine) in adult myeloid leukemia (AML). The committee found that the single-arm clinical study results submitted to support the label expansion showed Clolar was an active agent in acute AML patients, but concluded that a randomized clinical trial should be necessary to better interpret Clolar’s efficacy and safety in the proposed patient population.

2 Sep 2009

Ono Pharmaceutical secures exclusive rights to develop and commercialize asimadoline in Japan

Tioga Pharmaceuticals, Inc. and Ono Pharmaceutical Co, Ltd. Osaka, Japan today announced an exclusive license agreement under which Ono has licensed rights to develop and commercialize asimadoline in Japan, South Korea and Taiwan. Tioga retains all other rights to asimadoline.

2 Sep 2009

Members of Independence Blue Cross will receive coverage for the administration costs of the H1N1 vaccine

In an effort to help keep members healthy and flu-free this year, Independence Blue Cross (IBC) will offer coverage for the administration costs of the H1N1 (swine flu) vaccine when it becomes available. In addition IBC will continue to cover seasonal flu vaccine.

2 Sep 2009

Eye disease medication lowers death rate among Ethiopian children

Children in Ethiopia who received the antibiotic azithromycin as a method for controlling the contagious eye disease trachoma had a lower odds of death compared to children who did not receive the antibiotic, according to a study in the September 2 issue of JAMA.

2 Sep 2009

Traditional lipid risk factors to be strong predictors of cardiovascular events according to a study

For patients with established heart disease who were treated with a statin, 18 novel biomarkers including C-reactive protein (CRP) did not predict future cardiovascular events such as heart attack and stroke, according to results of an analysis presented today at the 2009 European Society of Cardiology Congress in Barcelona, Spain.

1 Sep 2009

Diarrhea News and Research

Latest Diarrhea News and Research

Under-five mortality rate continues to decline

Students do not comply with basic preventative measures to combat H1N1

FDA approves Supplemental New Drug Application for DOXIL

UNICEF data shows global child mortality now below 9m, progress not enough to achieve MDG in most regions

South East Asian health ministers adopt declaration to improve disaster preparedness, address childhood diarrhea

Caldolor launched ahead of schedule in U.S. by Cumberland Pharmaceuticals

Ceragenix awarded $2.87M NIH grant to develop a drug for treating Clostrdium difficile and Shigella

Meda launches EDLUAR in the U.S.

Study to test efficacy of lapatinib in advanced hepatocellular carcinoma

DOR's Phase 1/2 clinical trial for prevention of radiation enteritis receives NIH grant

Third human clinical trial of LigoCyte's norovirus vaccine started

Results of Phase 2 rheumatoid arthritis clinical trial announced

Recurrence of Clostridium difficile infection is a growing area of concern in hospitals

Millennium's sNDA to be reviewed by the FDA

Antibiotic used to treat trachoma reduces child mortality in Ethiopia, study finds

FDA: Randomized clinical trial necessary to better interpret Clolar’s efficacy and safety in adult AML

Ono Pharmaceutical secures exclusive rights to develop and commercialize asimadoline in Japan

Members of Independence Blue Cross will receive coverage for the administration costs of the H1N1 vaccine

Eye disease medication lowers death rate among Ethiopian children

Traditional lipid risk factors to be strong predictors of cardiovascular events according to a study

Achieving and maintaining ISO/IEC 27001 and BS 10012 certifications

Expanding research and clinical options for children with cancer

Examining how pain could play a direct protective role in the gut

Diarrhea News and Research

Latest Diarrhea News and Research

Achieving and maintaining ISO/IEC 27001 and BS 10012 certifications

Expanding research and clinical options for children with cancer

Examining how pain could play a direct protective role in the gut

Newsletters you may be interested in